Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. insider activity: President, CEO, director and 10% owner Paul Badawi reported two sales of the company’s common stock. On January 2, 2026, he sold 25,356 shares at a weighted average price of $7.43 per share, and on January 6, 2026, he sold 11,870 shares at a weighted average price of $7.48 per share.
According to the footnotes, the January 2 sale reflects shares sold to cover his tax liability arising from the vesting of restricted stock units. Both trades were executed in multiple transactions within disclosed price ranges. After these transactions, Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.
Sight Sciences Chief Operating Officer Alison Bauerlein reported two open-market sales of company common stock. On January 5, 2026, she sold 10,896 shares at a weighted average price of $7.82 per share, and on January 6, 2026, she sold 9,647 shares at a weighted average price of $7.48 per share.
According to the footnotes, these sales were made to cover her tax liability arising from the vesting of restricted stock units, meaning they were linked to equity compensation rather than a discretionary reduction in holdings. After these transactions, she beneficially owned 599,983 shares of Sight Sciences common stock directly.
Sight Sciences executive Brenton Taylor, EVP of Operations & R&D, reported a small sale of company stock mainly to cover taxes from vesting equity. On January 6, 2026, he sold 619 shares of Sight Sciences common stock at a weighted average price of $7.48 per share, through multiple trades priced between $7.39 and $7.67. After this tax-related sale, he directly holds 170,212 shares of the company’s common stock.
Sight Sciences insider Jeremy Hayden has filed a notice of proposed stock sales under Rule 144. The filing states an intention to sell 1,785 shares of Sight Sciences common stock through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of January 6, 2026 and an aggregate market value of $13,354.66. These shares were acquired on January 2, 2026 via restricted stock vesting from the issuer as compensation.
The notice also lists recent sales over the prior three months by the same seller, including 3,150 shares sold on November 12, 2025 for gross proceeds of $25,227.78, 44,850 shares sold on November 25, 2025 for $362,596.77, and 9,385 shares sold on January 5, 2026 for $73,418.85. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the company.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 13,958 shares of common stock on 12/16/2025 at a weighted average price of $8.308 per share. The shares were bought in multiple trades at prices ranging from $8.12 to $8.40.
After this transaction, Encrantz directly beneficially owns 1,391,922 shares, which include 30,952 restricted stock units subject to vesting. He is also reported as having indirect beneficial ownership of 632,456 shares held by a revocable trust where he serves as trustee, and 5,086,920 shares held by Allegro Investment Fund, L.P., although he disclaims pecuniary interest and beneficial ownership in the Allegro-held shares.
Sight Sciences, Inc. (SGHT) reported an insider transaction by its EVP, Operations & R&D, Brenton Taylor. On 11/17/2025, Taylor sold 14,418 shares of common stock at a weighted average price of $7.06 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units. After this transaction, Taylor beneficially owned 170,831 shares of Sight Sciences common stock.
Sight Sciences, Inc. (SGHT) filed a Form 4 reporting equity transactions by Chief Legal Officer Jeremy Hayden. On 11/12/2025, he exercised stock options for 2,440 shares of common stock at $1.96 per share and an additional 710 shares at the same exercise price, all under the company’s equity incentive plan.
The same day, 3,150 shares of common stock were sold at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06. Following these transactions, Hayden beneficially owned 256,590 shares of common stock directly. The filing states the transactions were made under a Rule 10b5-1 trading plan tied to a marital separation agreement, and that his former spouse will receive all proceeds from the share sales.
Sight Sciences (SGHT) reported an insider equity grant. Chief Operating Officer Alison Bauerlein acquired 23,006 RSUs on November 11, 2025 under the company’s 2021 Incentive Award Plan at a stated price of $0 per unit. The award equals approximately $150,000 of common stock based on the grant-date price, with each RSU representing one share.
The RSUs vest in 16 equal quarterly installments from December 31, 2025 through September 30, 2029, contingent on continued service. Following this grant, Bauerlein beneficially owned 620,526 shares directly.
Sight Sciences (SGHT) disclosed a Form 4 for its Chief Financial Officer, reporting an equity award tied to service. On November 11, 2025, the officer acquired 15,337 shares of common stock at $0, reflecting settlement of a new grant of restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan. Following the transaction, the officer beneficially owns 161,363 shares, held directly.
The RSU grant equals approximately $100,000 of common stock based on the grant-date price and vests in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Each RSU represents the right to receive one share of common stock and has no expiration date.
Sight Sciences (SGHT) reported an officer’s initial beneficial ownership on Form 3 effective 11/05/2025. The Chief Financial Officer beneficially owns 146,026 shares, including 28,252 shares of common stock and 117,774 restricted stock units subject to vesting conditions. Derivative holdings include stock options for 27,500 shares at $10.96 expiring 05/24/2031, 13,100 shares at $17.52 expiring 02/08/2032, and 14,400 shares at $9.78 expiring 03/16/2033, each with time-based monthly vesting as described.